Nebivolol
Bystolic, Byvalson (nebivolol) is a small molecule pharmaceutical. Nebivolol was first approved as Bystolic on 2007-12-17. It is used to treat malignant hypertension in the USA. It is known to target beta-3 adrenergic receptor, beta-2 adrenergic receptor, and beta-1 adrenergic receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
Trade Name
FDA
EMA
Bystolic (generic drugs available since 2015-04-16)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| malignant hypertension | EFO_1001031 | D006974 | — |
Agency Specific
FDA
EMA
No data
ATC Codes
C: Cardiovascular system drugs
— C07: Beta-adrenergic blocking agents
— C07A: Beta blocking agents
— C07AB: Beta blocking agents, selective
— C07AB12: Nebivolol
— C07B: Beta blocking agents and thiazides
— C07BB: Beta blocking agents, selective, and thiazides
— C07BB12: Nebivolol and thiazides
— C07F: Beta blocking agents, other combinations
— C07FB: Beta blocking agents and calcium channel blockers
— C07FB12: Nebivolol and amlodipine
— C09: Agents acting on the renin-angiotensin system
— C09D: Angiotensin ii receptor blockers (arbs), combinations
— C09DX: Angiotensin ii receptor blockers (arbs), other combinations
— C09DX05: Valsartan and nebivolol
HCPCS
No data
Clinical
Clinical Trials
10 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Aplastic anemia | D000741 | HP_0001915 | D61.9 | 1 | 1 | 1 | — | — | 2 |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | — | — | 1 | — | — | 1 |
| Pancytopenia | D010198 | HP_0001876 | D61.81 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hip fractures | D006620 | EFO_0003964 | S72.00 | — | 1 | — | — | — | 1 |
| Idiopathic pulmonary fibrosis | D054990 | J84.112 | 1 | 1 | — | — | — | 1 | |
| Bone marrow failure disorders | D000080983 | 1 | 1 | — | — | — | 1 | ||
| Telomere shortening | D059506 | 1 | 1 | — | — | — | 1 | ||
| Critical illness | D016638 | — | 1 | — | — | — | 1 | ||
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Contraception | D003267 | 2 | — | — | — | — | 2 | ||
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | — | — | — | — | 1 |
| Hiv wasting syndrome | D019247 | EFO_0007312 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | — | — | — | 1 | 1 |
| Muscle weakness | D018908 | HP_0001324 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | NEBIVOLOL |
| INN | nebivolol |
| Description | 2,2'-iminobis[1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)ethanol] is a member of the class of chromanes that is 2,2'-iminodiethanol in which one hydrogen attached to each hydroxy-bearing carbon is replaced by a 6-fluorochroman-2-yl group. It is an organofluorine compound, a secondary amino compound, a secondary alcohol, a diol and a member of chromanes. |
| Classification | Small molecule |
| Drug class | beta-blockers (propranolol type) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | OC(CNCC(O)C1CCc2cc(F)ccc2O1)C1CCc2cc(F)ccc2O1 |
Identifiers
| PDB | — |
| CAS-ID | 99200-09-6 |
| RxCUI | 31555 |
| ChEMBL ID | CHEMBL434394 |
| ChEBI ID | 64019 |
| PubChem CID | 71301 |
| DrugBank | DB04861 |
| UNII ID | 030Y90569U (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
ADRB3
ADRB3
ADRB2
ADRB2
ADRB1
ADRB1
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,819 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
31 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more